“Developing traditional Chinese medicine into FDA-approved

prescription drugs for the treatment of cancer”

PhytoCeutica is focused on the development of traditional Chinese medicine (TCM) into FDA-approved prescription drugs for the treatment of cancer through relevant preclinical studies, high-quality standardization, and rigorous clinical investigations. Chinese medicine has a long, rich, and well-respected history that is grounded in thousands of years of human use. Combining this ancient experience-based knowledge with objective, evidence-based scientific studies will engender botanical formulations with a proven, therapeutic utility for serious life-threatening diseases such as cancer. 

PhytoCeutica is actively pursuing FDA approval for its lead herbal formulation, PHY906, as a broad-spectrum adjuvant to conventional chemotherapy, and a second formulation, PHY818, for enhancing white blood cell counts depleted from chemotherapy or radiation therapy.  PhytoCeutica also plays a leadership role in the development of a powerful and novel platform technology, PhytomicsQC™, that employs high-resolution chemical and biological response fingerprints to characterize high-quality botanical formulations.

The challenge of developing prescription-quality botanical drugs is difficult. The importance, however, is enormous.

PhytoCeutica, Inc.

5 Science Park, Suite 13

New Haven, CT  06511

Phone: 203-777-3462

Fax: 203-777-3538

E-mail: info@phytoceutica.com

Recent Updates

> June 2005

Du-Shieng Chien, Ph.D., of SunTen PhytoTech and Matthew Smith of Connecticut
Innovations join the PhytoCeutica Board of Directors.

> March 26, 2005

PHY906 + capecitabine hepatocellular carcinoma clinical trial: phase I dose
of PHY906 600 mg BID + capecitabine 750 mg/m(squared) found to be safe.

 > January 2005

PHY906 has been allowed for issuance as a patent in the U.S.